Alterity Therapeutics (ASX: ATH) — Company Overview, News & Financial Data
Alterity Therapeutics is a clinical-stage biotechnology company focused on creating disease-modifying therapies for neurodegenerative disorders.
Alterity Therapeutics
Alterity Therapeutics is a clinical-stage biotechnology company focused on creating disease-modifying therapies for neurodegenerative disorders. The company develops targeted small molecule drug candidates aimed at disrupting the underlying pathology of complex neurodegenerative conditions. Its primary lead candidate, ATH434, is designed to inhibit alpha-synuclein aggregation and address pathological iron accumulation in the brain. ATH434 is currently being evaluated in clinical trials for Parkinsonian disorders, including Multiple System Atrophy. Through its drug discovery platform, the company also researches early-stage compounds targeting iron dysregulation and neuroinflammation across broader central nervous system indications.
Snapshot
Operations
Products and/or services of Alterity Therapeutics
- Multiple System Atrophy Program: Clinical-stage drug development evaluating a lead oral small molecule to reduce toxic alpha-synuclein accumulation and labile iron in brain regions affected by Multiple System Atrophy, a rare and rapidly progressive neurodegenerative movement disorder.
- Parkinsonian Disorders Research: Preclinical and clinical investigation of lead iron-chaperone candidates across related adult-onset Parkinsonian movement disorders, targeting focal iron dysregulation, oxidative toxicity, and neuronal degradation in central nervous system structures.
- Small Molecule Drug Discovery: Development of next-generation oral therapeutics designed to cross the blood-brain barrier and selectively target pathological iron redistribution, protein misfolding, and neuroinflammation across broader central nervous system conditions.
- Iron Redistribution Platform: Research into proprietary therapeutic mechanisms that redistribute labile iron within neural cells, preventing neurotoxic damage while maintaining essential cellular iron homeostasis across neurodegenerative disease pathologies.
Alterity Therapeutics executive team
- David A. StamlerCEO, MD & Director
- Abby Macnish NivenCFO & Company Secretary
- Rudolph Emile TanziChief Scientific Advisor and Member of Research & Development Advisory Board
- Steven D. TargumChief Medical Advisor
- Robert ChernyHead of Research
Latest news about Alterity Therapeutics
Recent announcements
What Alterity Therapeutics (ATH) has told the market, newest first.
- Alterity to Present at Canaccord Drug and Device Conference
- Alterity Presents New Analyses of ATH434 Phase 2 Data in MSA
- Change of Director's Interest Notice x 2
- Corporate Presentation June 2026
Key financials
Reported results for Alterity Therapeutics, in AUD.
- Market cap
- 55.7M
- Revenue (TTM)
- 3.6M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.1
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 0 | -28.4M | -23.4M | |
| 5.4M | -14.6M | -12.1M | |
| 4M | -19.6M | -19.1M | |
| 3.9M | -14.6M | -13.8M |